Incyte Corporation (INCY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Incyte Corporation (INCY) has a cash flow conversion efficiency ratio of 0.067x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($369.35 Million) by net assets ($5.55 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Incyte Corporation balance sheet independence to measure how much of total assets are equity-financed.
Incyte Corporation - Cash Flow Conversion Efficiency Trend (1993–2025)
This chart illustrates how Incyte Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Incyte Corporation cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Incyte Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Incyte Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BioNTech SE
F:22UA
|
-0.023x |
|
Amer Sports, Inc.
NYSE:AS
|
0.107x |
|
MKS Instruments Inc
NASDAQ:MKSI
|
0.019x |
|
Northern Star Resources Ltd
AU:NST
|
0.068x |
|
LyondellBasell Industries NV
NYSE:LYB
|
-0.026x |
|
Snap-On Inc
NYSE:SNA
|
0.045x |
|
MTN Group Ltd
JSE:MTN
|
0.255x |
|
Pernod Ricard S.A.
PA:RI
|
0.110x |
Annual Cash Flow Conversion Efficiency for Incyte Corporation (1993–2025)
The table below shows the annual cash flow conversion efficiency of Incyte Corporation from 1993 to 2025. For the full company profile with market capitalisation and key ratios, see Incyte Corporation market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.15 Billion | $1.41 Billion | 0.274x | +181.93% |
| 2024-12-31 | $3.45 Billion | $335.34 Million | 0.097x | +1.67% |
| 2023-12-31 | $5.19 Billion | $496.49 Million | 0.096x | -56.90% |
| 2022-12-31 | $4.37 Billion | $969.94 Million | 0.222x | +11.64% |
| 2021-12-31 | $3.77 Billion | $749.49 Million | 0.199x | +516.64% |
| 2020-12-31 | $2.61 Billion | $-124.60 Million | -0.048x | -117.45% |
| 2019-12-31 | $2.60 Billion | $710.66 Million | 0.273x | +56.66% |
| 2018-12-31 | $1.93 Billion | $336.23 Million | 0.175x | +406.13% |
| 2017-12-31 | $1.63 Billion | $-92.99 Million | -0.057x | -107.85% |
| 2016-12-31 | $419.47 Million | $304.76 Million | 0.727x | +43.70% |
| 2015-12-31 | $171.16 Million | $86.54 Million | 0.506x | +192.50% |
| 2014-12-31 | $-48.04 Million | $26.26 Million | -0.547x | -1049.79% |
| 2013-12-31 | $-193.11 Million | $9.18 Million | -0.048x | -108.77% |
| 2012-12-31 | $-174.96 Million | $-94.83 Million | 0.542x | -23.89% |
| 2011-12-31 | $-227.08 Million | $-161.72 Million | 0.712x | +164.46% |
| 2010-12-31 | $-88.64 Million | $97.94 Million | -1.105x | -815.35% |
| 2009-12-31 | $-102.38 Million | $12.36 Million | -0.121x | -118.92% |
| 2008-12-31 | $-220.75 Million | $-140.86 Million | 0.638x | +9.81% |
| 2007-12-31 | $-159.52 Million | $-92.69 Million | 0.581x | -2.04% |
| 2006-12-31 | $-84.91 Million | $-50.37 Million | 0.593x | -88.71% |
| 2005-12-31 | $-19.40 Million | $-101.87 Million | 5.252x | +459.62% |
| 2004-12-31 | $78.52 Million | $-114.67 Million | -1.460x | -90.47% |
| 2003-12-31 | $154.33 Million | $-118.33 Million | -0.767x | -297.95% |
| 2002-12-31 | $302.41 Million | $-58.27 Million | -0.193x | -80.44% |
| 2001-12-31 | $440.20 Million | $-47.00 Million | -0.107x | -805.37% |
| 2000-12-31 | $622.69 Million | $-7.34 Million | -0.012x | +90.61% |
| 1999-12-31 | $170.30 Million | $-21.40 Million | -0.126x | -162.34% |
| 1998-12-31 | $179.60 Million | $36.20 Million | 0.202x | +50.58% |
| 1997-12-31 | $139.70 Million | $18.70 Million | 0.134x | -62.19% |
| 1996-12-31 | $45.20 Million | $16.00 Million | 0.354x | +284.07% |
| 1995-12-31 | $46.80 Million | $-9.00 Million | -0.192x | +26.74% |
| 1994-12-31 | $24.00 Million | $-6.30 Million | -0.263x | +3.95% |
| 1993-12-31 | $16.10 Million | $-4.40 Million | -0.273x | -- |
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chr… Read more